-
Something wrong with this record ?
Use of enzymes in complex treatment of antiphospholipid syndrome in women with reproductive losses of andijan state
Gulnoza Maniyozova, Habiba Negmatshaeva, Ozoda Yuldasheva, Gulnoza Turaeva, Dilfura Parpieva
Language English Country Czech Republic Media elektronický zdroj
Document type Evaluation Study
Digital library NLK
Full text - Article
Issue
Volume
Source
Source
NLK
ROAD: Directory of Open Access Scholarly Resources
from 2011 to 2017
- Keywords
- Serrata,
- MeSH
- Anti-Inflammatory Agents therapeutic use MeSH
- Antiphospholipid Syndrome * etiology drug therapy blood MeSH
- Antioxidants therapeutic use MeSH
- Enzyme Therapy * methods statistics & numerical data MeSH
- Fibrinolytic Agents therapeutic use MeSH
- Hemostasis drug effects MeSH
- Cohort Studies MeSH
- Pregnancy Complications * prevention & control MeSH
- Humans MeSH
- Abortion, Spontaneous prevention & control MeSH
- Pregnancy MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Evaluation Study MeSH
Background: Obstetric complications developing at antiphospholipid syndrome are serious medical-social problem. Seeking of the treatment methods sets conditions for urgency of the article reviewed. Enzyme preparations are widely applied for treatment of women with fecundity disorder and hemorheology changes. Research objective was in clinico-laboratorial evaluation of Serrata drug impact in antiphospholipid syndrome in women with reproductive losses of Andijan state. Methods: Data of 43 women in the non-pregnancy state with reproductive losses (RL) in past history with revealed APS had been studied by us. Results: Thus, conducted therapy with Serrata was conductive to haemostasis. Conducted researches confirm the safety of application.
Use of enzymes in complex treatment of antiphospholipid syndrome in women with reproductive losses of andijan state [elektronický zdroj] /
References provided by Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15010747
- 003
- CZ-PrNML
- 005
- 20190528130107.0
- 007
- cr|cn|
- 008
- 150322s2014 xr fs 000 0|eng||
- 009
- eAR
- 024 7_
- $a 10.12955/emhpj.v7i2.502 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Maniyozova, Gulnoza $u The Andijan State Medical Institute, Andijan, Uzbekistan
- 245 10
- $a Use of enzymes in complex treatment of antiphospholipid syndrome in women with reproductive losses of andijan state $h [elektronický zdroj] / $c Gulnoza Maniyozova, Habiba Negmatshaeva, Ozoda Yuldasheva, Gulnoza Turaeva, Dilfura Parpieva
- 504 __
- $a Literatura
- 520 9_
- $a Background: Obstetric complications developing at antiphospholipid syndrome are serious medical-social problem. Seeking of the treatment methods sets conditions for urgency of the article reviewed. Enzyme preparations are widely applied for treatment of women with fecundity disorder and hemorheology changes. Research objective was in clinico-laboratorial evaluation of Serrata drug impact in antiphospholipid syndrome in women with reproductive losses of Andijan state. Methods: Data of 43 women in the non-pregnancy state with reproductive losses (RL) in past history with revealed APS had been studied by us. Results: Thus, conducted therapy with Serrata was conductive to haemostasis. Conducted researches confirm the safety of application.
- 650 12
- $a antifosfolipidový syndrom $x etiologie $x farmakoterapie $x krev $7 D016736
- 650 _2
- $a samovolný potrat $x prevence a kontrola $7 D000022
- 650 12
- $a komplikace těhotenství $x prevence a kontrola $7 D011248
- 650 _2
- $a fibrinolytika $x terapeutické užití $7 D005343
- 650 _2
- $a antiflogistika $x terapeutické užití $7 D000893
- 650 12
- $a enzymoterapie $x metody $x statistika a číselné údaje $7 D057487
- 650 _2
- $a antioxidancia $x terapeutické užití $7 D000975
- 650 _2
- $a hemostáza $x účinky léků $7 D006487
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a výsledek terapie $7 D016896
- 653 00
- $a Serrata
- 655 _2
- $a hodnotící studie $7 D023362
- 700 1_
- $a Negmatshaeva, Habiba $u The Andijan State Medical Institute, Andijan, Uzbekistan
- 700 1_
- $a Yuldasheva, Ozoda $u The Andijan State Medical Institute, Andijan, Uzbekistan
- 700 1_
- $a Turaeva, Gulnoza $u The Andijan State Medical Institute, Andijan, Uzbekistan
- 700 1_
- $a Parpieva, Dilfura $u The Andijan State Medical Institute, Andijan, Uzbekistan
- 773 0_
- $t European medical, health and pharmaceutical journal $x 1804-5804 $g Roč. 7, č. 2 (2014), s. 1-2 $w MED00177703
- 856 41
- $u https://ojs.journals.cz/index.php/EMHPJ/issue/view/54 $y plný text volně přístupný
- 910 __
- $a ABA008 $y 4 $z 0
- 990 __
- $a 20150321103405 $b ABA008
- 991 __
- $a 20190528130232 $b ABA008
- 999 __
- $a ok $b bmc $g 1068198 $s 893585
- BAS __
- $a 3 $a 4 $a PRD
- BMC __
- $a 2014 $b 7 $c 2 $d 1-2 $i 1804-5804 $m European Medical, Health and Pharmaceutical Journal $n Eur. Med. Health Pharm. J. $x MED00177703
- LZP __
- $c NLK121 $d 20151116 $a NLK 2015-16/vt